• Review • Previous Articles     Next Articles

A new target of antiplatelet therapy: glycoprotein Ⅵ

上海交通大学 医学院附属第三人民医院心内科, 上海 201999   

  1. Department of Cardiology, Shanghai Third People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China
  • Online:2015-07-28 Published:2015-08-27
  • Supported by:

    Shanghai Shen-Kang Technique Expansion Project, SHDC12012210; Baoshan District Science and Technology Commission Project, 12-E-63

Abstract:

Antiplatelet therapy plays a significant role in the treatment of cardiovascular disease. Now there are many drugs available for clinical application, but the curative effect is unsatisfactory. Complications such as bleeding are major problems. So it is urgent to find efficient and safe new drugs. Glycoprotein Ⅵ (GP Ⅵ) is one of the many receptors on platelet membrane and is also a new direction for developing antithrombotic drugs. This paper reviews studies relevant to GP Ⅵ.

Key words: glycoprotein Ⅵ, platelet, artery atherosclerotic